Fig. 3: Effects of obesity on oestrogen signalling.
From: Targeting obesity-related dysfunction in hormonally driven cancers
AI aromatase inhibitor, GnRH gonadotropin releasing hormone, SERM selective estrogen receptor modulator (i.e; tamoxifen), SERDselectve receptor degrader (i.e.; fulvestrant), CDK4/6 cyclin dependent kinases 4 and 6 inhibitors, GPER G-coupled estrogen receptor.
